文献速递其他结缔组织病

静脉注射免疫球蛋白治疗硬化性黏液水肿的临床与分子表型分析

Clinical and Molecular Phenotyping in Scleromyxedema Pretreatment and Posttreatment With Intravenous Immunoglobulin.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2020-05-14

治疗后MMRSS评分及皮肤柔韧性、软化度均显著改善,Tc17细胞基线水平与MMRSS相关且治疗后下降,皮肤TGFβ及干扰素诱导蛋白基因表达降低。

要点

  • IVIG治疗后MMRSS平均从13.6降至10.3(P=0.003),皮肤柔韧性和软化度亦显著改善。
  • 基线Tc17细胞水平与MMRSS相关(r=0.69,P=0.012),治疗后显著下降(P=0.008)。
  • 皮肤组织RNA分析显示TGFβ细胞因子及多个干扰素诱导蛋白基因表达降低。

核心结论

  • IVIG治疗可使硬化性黏液水肿患者获得客观和主观的临床改善。
  • 生物学研究提示T淋巴细胞可能参与疾病发病机制,并揭示TGFβ和干扰素通路的潜在意义。

研究设计与样本

  • 在IVIG治疗前及治疗后1-2周采集临床信息和外周血单个核细胞进行流式细胞术。
  • 其中10例患者在IVIG治疗前后进行皮肤活检用于基因表达分析。

主要发现

  • 治疗后平均MMRSS评分从13.6±2.6降至10.3±1.9(P=0.003)。
  • 皮肤柔韧性从5.4±0.8改善至3.2±0.7(P=0.003),软化度从4.9±0.9改善至2.6±0.6(P=0.022)。
  • 基线Tc17细胞(CD8+CCR6+CXCR3+CCR4-)水平与治疗前MMRSS测量的皮肤受累范围相关(r=0.69,P=0.012)。
  • IVIG治疗后Tc17细胞水平从3.4%±3.2%降至1.3%±1.7%(P=0.008)。
  • 皮肤组织RNA分析显示TGFβ细胞因子及多个干扰素诱导蛋白的基因表达降低。

临床怎么用

  • 对于硬化性黏液水肿患者,IVIG治疗可考虑用于改善皮肤受累的客观指标和患者报告结局。
  • Tc17细胞水平和TGFβ/干扰素通路可能作为未来评估疾病活动或治疗反应的候选生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Scleromyxedema (SMX) is a rare systemic sclerosis mimic that often responds to intravenous immunoglobulin (IVIG) therapy, yet the resulting clinical and biochemical changes have not been well characterized. To better understand the pathogenesis of the disease and the efficacy of IVIG, we sought to explore whether IVIG would introduce a measurable biologic effect corresponding with clinical improvement. METHODS: Fifteen patients with SMX were recruited for the study. Clinical information and peripheral blood mononuclear cells for flow cytometry were obtained immediately before and again 1-2 weeks after patients received IVIG therapy. Ten patients also underwent skin biopsies for gene expression analysis both before and after IVIG therapy. Clinical data included measures of skin involvement (modification of the modified Rodnan skin thickness score [MMRSS] and percentage of body surface area) and several patient-reported outcome measures assessing patients' skin. RESULTS: Posttreatment, the average MMRSS score decreased from mean ± SD 13.6 ± 2.6 to 10.3 ± 1.9; P = 0.003. There were also significant improvements in skin flexibility (mean ± SD 5.4 ± 0.8 to 3.2 ± 0.7; P = 0.003) and softening (mean ± SD 4.9 ± 0.9 to 2.6 ± 0.6; P = 0.022). Baseline levels of Tc17 cells (CD8+CCR6+CXCR3+CCR4-) correlated with the extent of skin involvement as measured by MMRSS pretreatment (r = 0.69, P = 0.012) and decreased after IVIG therapy (mean ± SD 3.4% ± 3.2% to 1.3% ± 1.7%; P = 0.008). Posttreatment analysis of RNA in skin tissue revealed a decrease in gene expression of transforming growth factor β (TGFβ) cytokines as well as several interferon-inducible proteins. CONCLUSION: This open-label study further supports the evidence that patients with SMX respond both objectively and subjectively to IVIG therapy. Biologic studies suggest a role for T lymphocytes in the pathogenesis of the disease and reveal the potential significance of TGFβ and interferon pathways.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Mecoli CA, Talbot CC, Fava A, et al. Clinical and Molecular Phenotyping in Scleromyxedema Pretreatment and Posttreatment With Intravenous Immunoglobulin. Arthritis Care Res (Hoboken). 2020. PMID: 31008568. doi:10.1002/acr.23908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。